

---

**PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FINANCIAL RESULTS  
FOR HALF YEAR ENDED 30 JUNE 2022**

---

The Board of Directors (the “**Board**”) of Pharmesis International Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) wishes to announce that after preliminary assessment of the Group’s unaudited financial results, the Board would like to inform the shareholders and investors that the Group is expected to report a net loss for the unaudited financial results for the half year ended 30 June 2022 (“**1HFY22**”).

The expected net loss was mainly due to the control measures such as lockdowns taken by China to contain the spread of the COVID-19 pandemic, which has resulted in a decrease in our sales.

Further details of the Group’s financial performance will be disclosed when the Company announces its unaudited financial results for 1HFY22.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

**BY ORDER OF THE BOARD**

Wu Xuedan  
Executive Director and Chief Executive Officer  
5 August 2022